{"filings":[{"id":1205396,"accession_number":"0001110803-26-000138","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2026-06-23T13:08:49+00:00","items":["5.02","9.01"],"status":"ready","headline":"Illumina appoints Eli Lilly's CSO Daniel Skovronsky to Board effective June 16, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board effective June 16, 2026; Board expanded to 10 members.","Skovronsky is Eli Lilly's Chief Scientific and Product Officer and President of Lilly Research Laboratories.","He brings expertise in drug discovery, clinical development, and translational medicine to Illumina's genomics focus.","Skovronsky will participate in the standard non-employee director compensation program described in April 9, 2026 proxy.","He qualifies as an independent director under Nasdaq and SEC rules; will stand for election at 2027 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":670319,"accession_number":"0001110803-26-000124","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2026-05-26T21:28:17+00:00","items":["5.07","9.01"],"status":"ready","headline":"Illumina shareholders elect all nine board nominees; ratify auditor and say-on-pay at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected; Anna Richo received 8.4M against votes (6.5% of votes cast).","Ernst & Young ratified as independent auditor for FY ending Jan 3, 2027 with 133.2M for, 7.8M against.","Advisory approval of named executive officer compensation passed with 121.7M for, 8.5M against.","Quorum of 141.0M votes (92.85% of outstanding shares) present at May 21, 2026 meeting.","Final voting results certified by Inspector of Election on May 22, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91362,"accession_number":"0001110803-26-000087","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Illumina Q1 revenue up 4.8% to $1.09B; non-GAAP EPS $1.15, raises FY2026 guidance; new $1.5B buyback","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.09B (+4.8% YoY); GAAP EPS $0.87, non-GAAP EPS $1.15 vs prior year $0.97.","GAAP operating margin 19.2%, non-GAAP 21.9%; free cash flow $251M vs $208M prior year.","FY2026 guidance raised: revenue $4.52-$4.62B, non-GAAP EPS $5.15-$5.30.","Board authorized new $1.5B share repurchase program; $314M remains from prior $1.5B authorization.","Cash and short-term investments $1.16B; operating cash flow $289M."],"consensus_eps_estimate":null,"consensus_eps_actual":0.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":1091000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91361,"accession_number":"0001110803-26-000082","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Illumina names David King to board; three directors to retire in May 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Drs. Frances Arnold, Robert Epstein, and Gary Guthart will retire as directors effective May 21, 2026.","Retirements are not due to any dispute with the company or board.","Board nominated David P. King for election at the 2026 annual meeting.","King brings operating, board, and regulatory experience across healthcare and life sciences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101388,"accession_number":"0001110803-26-000018","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina Q4 revenue $1.16B (+5%), GAAP EPS $2.16; guides FY2026 rev $4.5-$4.6B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.16B in Q4 2025, up 5% YoY; ex-China revenue up 8%.","GAAP diluted EPS $2.16; non-GAAP diluted EPS $1.35.","FY2025 revenue $4.34B flat YoY; GAAP EPS $5.45, non-GAAP EPS $4.84.","FY2026 guidance: revenue $4.5-$4.6B (4-6% growth); non-GAAP EPS $5.05-$5.20.","Completed SomaLogic acquisition; China MOFCOM export ban lifted; launched Billion Cell Atlas with partners."],"consensus_eps_estimate":null,"consensus_eps_actual":5.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":4343000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101387,"accession_number":"0001110803-26-000014","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["2.01","8.01","9.01"],"status":"ready","headline":"Illumina completes $350M acquisition of SomaLogic from Standard BioTools","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price $350M in cash plus up to $75M in performance milestones and royalties.","SomaLogic's proteomics tech (SomaScan, SomaSignal) expands Illumina's multiomics portfolio.","Acquisition funded with cash on hand; financial impact discussed on Feb 5, 2026 earnings call.","Builds on co-development partnership established in 2021 for NGS-based proteomics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101386,"accession_number":"0001110803-26-000009","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina prelim Q4 rev $1.155B (+5% YoY); FY rev flat at $4.34B; EPS ranges given","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue ~$1.155B, up 5% YoY (4% constant currency); ex-China rev ~$1.1B up 7%.","FY2025 revenue ~$4.34B flat YoY; ex-China rev ~$4.1B up 2%.","Q4 GAAP diluted EPS $2.14-$2.17; non-GAAP diluted EPS $1.27-$1.30.","FY2025 GAAP diluted EPS $5.42-$5.45; non-GAAP $4.76-$4.79.","Full Q4/FY results expected after market close on Feb 5, 2026; preliminary numbers subject to audit."],"consensus_eps_estimate":null,"consensus_eps_actual":5.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":4343000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101385,"accession_number":"0001110803-26-000006","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Illumina appoints Dr. Eric Green as CMO; CCO Everett Cunningham resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Eric Green (former NHGRI director) named Chief Medical Officer, effective Feb 2, 2026.","Everett Cunningham resigns as Chief Commercial Officer effective Jan 16, 2026 to become CEO of a life science tools company.","CEO Jacob Thaysen will serve as interim CCO until a permanent successor is named.","Illumina to present at J.P. Morgan Healthcare Conference on Jan 13, 2026 at 7:30 AM PT."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117750,"accession_number":"0001193125-25-297576","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-11-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Illumina closes $500M 4.750% notes due 2030; proceeds for refinancing and SomaLogic acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Closed $500M public offering of 4.750% notes due December 12, 2030, issued under existing indenture.","Net proceeds earmarked to refinance $500M of 5.800% notes maturing Dec 2025 and fund SomaLogic acquisition.","Interest payable semi-annually at 4.750%; notes unsecured and may be redeemed at company's option.","Offering registered on Form S-3; trustee is U.S. Bank Trust Company, National Association."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117749,"accession_number":"0001193125-25-277870","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Illumina issues $500M of 4.750% notes due 2030, proceeds to repay existing debt and fund SomaLogic acquisition","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $500M aggregate principal of 4.750% notes due 2030 via underwriters Goldman Sachs & Co. LLC and BofA Securities.","Offering expected to close on November 25, 2025, subject to customary conditions.","Proceeds may be used to repay its 5.800% notes due December 12, 2025 and to fund the proposed SomaLogic acquisition and related fees.","Notes issued under existing shelf registration statement on Form S-3 (File No. 333-281921)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117748,"accession_number":"0001110803-25-000071","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina Q3 revenue $1.08B flat YoY, non-GAAP EPS $1.34 beats; raises FY EPS guidance to $4.65-$4.75","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 GAAP diluted EPS $0.98, non-GAAP diluted EPS $1.34; non-GAAP operating margin 24.5%.","Revenue $1.08B flat YoY on reported and constant currency; returned to growth ex-China.","FY2025 guidance raised: revenue decline narrowed to (1.5%)-(0.5%), non-GAAP EPS to $4.65-$4.75 from $4.45-$4.55.","Repurchased 1.2M shares for $120M at avg $97.10; cash flow from ops $284M, free cash flow $253M.","Launched new products: 5-base solution, Constellation mapped read tech, BioInsight, and Illumina Protein Prep."],"consensus_eps_estimate":null,"consensus_eps_actual":3.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":3184000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134191,"accession_number":"0001110803-25-000057","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina Q2 EPS $1.19 non-GAAP, revenue $1.06B; raises FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.059B down 3% YoY; GAAP EPS $1.49, non-GAAP EPS $1.19 vs. $1.09 prior year.","FY2025 guidance raised: revenue decline (2.5%)-(0.5%), non-GAAP op margin 22%-22.5%, EPS $4.45-$4.55.","Repurchased 4.5M shares for $380M at avg $84.66; ~$800M remaining authorization.","Signed definitive agreement to acquire SomaLogic from Standard BioTools; close expected H1 2026.","Q2 free cash flow $204M; cash and short-term investments $1.16B."],"consensus_eps_estimate":null,"consensus_eps_actual":2.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":2100000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150968,"accession_number":"0001193125-25-144290","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-06-23T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Illumina to acquire SomaLogic for $350M cash plus up to $75M milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Illumina will acquire SomaLogic's aptamer-based proteomics business from Standard BioTools for $350M cash at closing, plus up to $75M in milestones and royalties.","Transaction includes SomaLogic's SomaScan assay, CLIA/CAP lab in Boulder, CO, and ~250 employees; builds on co-development since 2021.","Illumina expects the business to become profitable on a non-GAAP basis in 2027, with operating margins in line with Illumina by 2028.","Closing expected in first half of 2026, subject to HSR and other customary conditions; termination fee of $14.5M under certain circumstances.","Illumina Protein Prep (SomaScan on NGS) already has ~40 early-access customers, full availability in Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150967,"accession_number":"0001110803-25-000051","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Illumina stockholders approve amended equity plan adding ~6.3M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved the Second Amended and Restated 2015 Stock and Incentive Plan, adding up to 6.3M new shares plus carryover from prior plan.","All 11 director nominees elected; Ernst & Young LLP ratified as independent auditor for FY2025.","Advisory say-on-pay passed with ~89% of votes cast (excluding broker non-votes).","Plan covers incentive stock options, nonstatutory options, stock grants, units, SARs, and cash awards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150966,"accession_number":"0001110803-25-000044","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina Q1 core rev $1.04B (-1% YoY) but cuts FY2025 guidance on tariffs & China","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.82; non-GAAP $0.97; GAAP op margin 15.8%, non-GAAP 20.4%.","FY2025 core revenue now seen declining 1-3% constant currency (prior low single-digit growth).","Non-GAAP EPS guidance cut to $4.20-$4.30 from ~$4.50; tariff costs estimated at $85M (125bps, $0.25 EPS).","Greater China 2025 revenue expected $165-$185M (Q1 recognition $72M); $100M cost reduction program initiated.","Q1 free cash flow $208M; $200M in share repurchases during quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":0.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":1041000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169874,"accession_number":"0001110803-25-000032","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-03-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Illumina elects Dr. Scott Gottlieb as Chair, appoints Keith Meister to board; Stephen MacMillan retires","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Scott Gottlieb elected non-executive Chair of Illumina's Board, effective March 28, 2025.","Keith Meister (Corvex Management founder) joins Board on March 28, 2025.","Stephen MacMillan resigns from Board effective March 28, 2025; no dispute with company.","Meister will stand for election at 2025 annual meeting; Gottlieb has served since 2020."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169873,"accession_number":"0001110803-25-000029","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-03-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Illumina CIO Carissa Rollins to retire effective April 11, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CIO Carissa Rollins notified Illumina on March 18, 2025 of her retirement.","Retirement effective as of April 11, 2025.","No replacement or interim CIO named in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169872,"accession_number":"0001110803-25-000025","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Illumina responds to China export ban, cuts FY2025 EPS guidance to ~$4.50","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["China MOFCOM prohibited Illumina from exporting sequencing instruments into China effective March 4, 2025.","FY2025 Core Illumina non-GAAP diluted EPS expected to be approximately $4.50.","Implementing incremental ~$100 million cost reduction program for FY2025 to offset China revenue impact.","CEO Jacob Thaysen reaffirms target of high-single-digit revenue growth by 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169871,"accession_number":"0001110803-25-000014","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina Q4 core revenue up 1% to $1.1B; FY2025 guided to low single-digit growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core Illumina Q4 revenue $1.104B (+1% YoY); GAAP EPS $0.73, non-GAAP EPS $0.95.","Full year core revenue $4.332B (-2% YoY); free cash flow $1.07B.","FY2025 guidance: core revenue $4.28B-$4.4B; non-GAAP Op margin ~23%; non-GAAP EPS $4.50-$4.65.","China Ministry of Commerce impact excluded from guidance; company notes current macro/political environment.","Key partnerships announced: NVIDIA, UK Biobank proteomics, Regeneron/Truveta Genome Project."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":4372000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169870,"accession_number":"0001110803-25-000009","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2025-01-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina reports Q4 core revenue $1.10B (+1% YoY); FY2025 outlook low-single-digit growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2024 core revenue $4.33B (-2% YoY constant currency); Q4 revenue $1.10B (+1% YoY).","GAAP diluted EPS: Q4 ~$0.77-$0.79, FY ~$5.65-$5.67; Non-GAAP Q4 ~$0.91-$0.93, FY ~$4.12-$4.14.","FY2025 guidance: reported revenue $4.28B-$4.4B, non-GAAP operating margin ~23%, non-GAAP EPS growth ~10%.","FY2024 free cash flow $1.07B (operating cash flow $1.21B less capex).","Preliminary results subject to completion of audit; final results expected Feb 6, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.69,"consensus_revenue_estimate":null,"consensus_revenue_actual":4372000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169869,"accession_number":"0001110803-25-000011","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K/A","filed_at":"2025-01-14T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Illumina records $14M additional impairment on San Diego property in Q4 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total $32M impairment in Q1 2024 from exiting Foster City campus and another San Diego property.","Additional $14M right-of-use asset impairment in Q4 2024 for the San Diego property; no remaining assets there.","Company continues to evaluate options for remaining Foster City campus.","All real estate exit charges will be excluded from non-GAAP financial metrics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186927,"accession_number":"0001110803-24-000049","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-11-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina Q3 Core revenue $1.08B (-2% YoY); raises FY24 non-GAAP EPS guide to $4.05-$4.15","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core Illumina revenue $1.08B, down 2% YoY; GAAP diluted EPS $4.03, non-GAAP $1.14.","Lowered FY2024 Core revenue guidance to ~3% decline; Q4 revenue expected ~$1.07B.","Raised FY2024 non-GAAP operating margin guidance to 21%-21.5% and non-GAAP diluted EPS to $4.05-$4.15.","Free cash flow $284M in Q3, up from $94M YoY; cash & short-term investments $939M.","Introduced MiSeq i100 Series, FDA approval for TSO Comprehensive, GRAIL spin-off completed June 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":3268000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186926,"accession_number":"0000950157-24-001364","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-10-03T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Illumina General Counsel Charles Dadswell to exit; Scott Davies named interim GC","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dadswell steps down as General Counsel and Secretary effective Oct 3, 2024; serves as advisor to CEO/Board through Mar 31, 2025.","Scott Davies, VP Legal – Chief Corporate Counsel, appointed Interim General Counsel and Secretary.","Dadswell eligible for $600K cash lump-sum payment plus regular compensation during advisory period upon satisfactory service.","Separation Agreement provides $620K severance (52 weeks salary), COBRA for 12 months, outplacement, and 2024 bonus if unpaid."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203468,"accession_number":"0001193125-24-215883","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["1.02","8.01","9.01"],"status":"ready","headline":"Illumina repays $761M credit facility, issues $500M 4.650% notes due 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Repaid all $761M outstanding under 364-day delayed draw credit agreement on Sept 9, 2024.","Issued $500M aggregate principal of 4.650% notes maturing Sept 9, 2026.","Net proceeds from notes plus cash on hand used to repay the credit facility.","Notes are unsecured, interest payable semi-annually; redeemable at Illumina's option.","Underwriters included J.P. Morgan Securities and Goldman Sachs & Co. LLC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203467,"accession_number":"0001193125-24-214335","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-09-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Illumina prices $500M of 4.650% notes due 2026; proceeds to repay GRAIL spin-off debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$500M aggregate principal of 4.650% notes maturing 2026 in an underwritten public offering.","Offering expected to close Sept 9, 2024, subject to customary closing conditions.","Net proceeds to repay part of $750M 364-day delayed draw credit agreement used for GRAIL spin-off.","Offering conducted under effective shelf registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203466,"accession_number":"0001110803-24-000042","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina Q2 core revenue $1.09B (-6% YoY); lowers FY2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core Illumina Q2 revenue $1.09B, down 6% YoY and 6% constant currency; up 3% from Q1.","Core Illumina GAAP EPS $0.41; non-GAAP EPS $1.09; non-GAAP operating margin 22.2%.","Lowered FY2024 core revenue guidance to decline 2-3% (constant currency down 1.5-2.5%).","Raised FY2024 non-GAAP operating margin guidance to 20.5-21%; non-GAAP EPS guidance $3.80-$3.95.","Consolidated GAAP net loss $1.988B includes $1.886B goodwill impairment on GRAIL; GRAIL spin-off completed June 24."],"consensus_eps_estimate":null,"consensus_eps_actual":-13.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":2188000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219887,"accession_number":"0001110803-24-000038","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K/A","filed_at":"2024-06-27T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Illumina estimates $1.466B goodwill and $420M IPR&D impairment charges for GRAIL in Q2 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Goodwill impairment charge of $1,466M related to GRAIL, representing full remaining carrying value as of March 31, 2024.","IPR&D intangible asset impairment charge of $420M for GRAIL in Q2 2024.","No material future cash expenditures expected from these impairment charges.","Charges will be excluded from non-GAAP financial metrics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219886,"accession_number":"0001110803-24-000037","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K/A","filed_at":"2024-06-27T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Illumina completes GRAIL spin-off; expects $1.9B in Q2 impairment charges","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Spin-off closed June 24, 2024; Illumina distributed 85.5% of GRAIL shares (1-for-6 ratio) and retained 14.5% stake.","Illumina contributed $974M cash to GRAIL (funded by a $750M 364-day term loan at ~6.69%, maturing June 2025).","Pro forma financials reflect expected Q2 2024 goodwill impairment of $1,466M and IPR&D impairment of $420M.","Pro forma for spin-off, 2023 net income would have been $219M vs. historical loss of $1,161M; Q1 2024 pro forma net income $56M vs. historical loss $126M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219894,"accession_number":"0001193125-24-167025","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["1.01","2.01","8.01","9.01"],"status":"ready","headline":"Illumina completes spin-off of GRAIL, retains 14.5% stake; GRAIL to trade as GRAL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Spin-off effective June 24, 2024: Illumina distributed 85.5% of GRAIL shares (1 share GRAIL per 6 shares ILMN), retains 14.5%.","GRAIL begins regular-way trading on Nasdaq as 'GRAL' on June 25, 2024.","Illumina drew $750M term loan at ~6.70% on June 20 to fund GRAIL's cash balance in connection with divestment.","Illumina to report Q2 2024 earnings on August 6 and host Strategy Update on August 13.","No gain/loss recognized for U.S. shareholders on distribution except for cash in lieu of fractional shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219893,"accession_number":"0001193125-24-162068","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-06-17T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Illumina enters $750M 364-day delayed draw credit facility for GRAIL divestiture funding","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Credit facility of $750 million entered June 17, 2024, with JPMorgan as administrative agent.","Proceeds to fund GRAIL's balance sheet in connection with planned GRAIL divestiture.","Facility expected to be drawn in full on June 20, 2024, maturing June 19, 2025.","Interest rate variable: currently approx 6.70%; based on SOFR or base rate plus spread.","No borrowings outstanding as of filing; covenant includes max total leverage ratio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219885,"accession_number":"0001193125-24-155272","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K/A","filed_at":"2024-06-06T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Illumina clarifies GRAIL spin-off dates: distribution effective June 24, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Distribution effective 12:01 A.M. NYC time on June 24; GRAIL begins regular-way trading June 25 under ticker GRAL.","GRAIL stock trades when-issued on Nasdaq as GRALV from June 12 through June 24.","Illumina common has two markets June 12–24: ILMN (with GRAIL entitlement) and ILMNV (ex-distribution). After June 25, only ILMN trades.","Spin-off is a pro rata dividend of at least 85.5% of GRAIL shares to Illumina stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219892,"accession_number":"0001193125-24-153239","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["2.05","8.01"],"status":"ready","headline":"Illumina board approves GRAIL spin-off; distribution set for June 24, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Holders receive 1 GRAIL share per 6 Illumina shares held at close on June 13, 2024 (record date).","Distribution effective 12:01 AM NYC time on June 24, 2024; GRAIL expected to trade 'regular way' on Nasdaq on June 25 under ticker 'GRAL'.","Illumina estimates $35-$50M incremental costs for spin-off, mainly legal and advisory fees, substantially incurred by Q3 2024.","Spin-off approval triggers potential goodwill impairment test; carrying value includes $1.466B goodwill and $561M IPR&D related to GRAIL.","Conditions include satisfaction or waiver of conditions in GRAIL's Form 10; no stockholder vote or action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219891,"accession_number":"0001110803-24-000030","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Illumina shareholders elect all 11 director nominees, ratify auditor, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 11 director nominees elected; Jacob Thaysen received highest support with 130.2M votes for.","Ernst & Young ratified as independent auditor for FY2024: 133.8M for, 6.8M against.","Advisory say-on-pay approved: 113.5M for, 16.7M against, 1.1M abstain.","Annual meeting held May 16, 2024; 141.8M shares represented in person or proxy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219884,"accession_number":"0001110803-24-000025","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K/A","filed_at":"2024-05-03T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Illumina records $75M in impairments on Foster City, San Diego campus exits; $142M assets at risk","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Recorded $43M right-of-use asset and leasehold improvement impairment in Q4 2023 for Foster City campus exit.","Additional $18M right-of-use asset impairment in Q1 2024 for Foster City and San Diego properties.","Recorded $14M leasehold improvement impairment in Q1 2024 related to Foster City campus.","Remaining assets on Foster City and San Diego properties total ~$142M as of March 31, 2024.","Company may incur further charges but cannot estimate timing or amount; charges excluded from non-GAAP."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219890,"accession_number":"0001110803-24-000019","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina Q1 2024: Core rev -2% to $1.06B; GAAP loss $0.79; GRAIL divestiture on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Core Illumina revenue $1.06B, down 2% YoY; GAAP operating margin 11.0%, non-GAAP 20.6%.","GAAP diluted loss per share ($0.79) vs. $0.02 EPS in Q1 2023; non-GAAP EPS $0.09 vs. $0.08.","FY2024 guidance reaffirmed: core revenue approximately flat YoY; non-GAAP operating margin ~20%.","GRAIL divestiture: received European Commission approval; target to finalize terms by end of Q2 2024.","In capital markets divestiture scenario, Illumina to provide GRAIL with ~$1B funding."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":1076000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219889,"accession_number":"0001110803-24-000013","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-04-12T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"EC approves Illumina's GRAIL divestment plan; $1B funding requirement for capital markets option","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["European Commission formally approved Illumina's Divestment Plan for GRAIL, LLC, per October 2023 divestment order.","Illumina may concurrently pursue a trade sale or a capital markets divestiture.","Capital markets transaction requires Illumina to capitalize GRAIL with ~$1B for 2.5 years of funding (includes GRAIL's cash).","Illumina reaffirms goal to finalize divestiture terms by end of Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219888,"accession_number":"0000950157-24-000591","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-04-09T23:59:59+00:00","items":["5.02","7.01","2.02","9.01"],"status":"ready","headline":"Illumina names Ankur Dhingra CFO; Joydeep Goswami departs; Q1/FY24 guidance reaffirmed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ankur Dhingra appointed CFO effective April 15, 2024; previously CFO of Summit Therapeutics (SMMT) and CareDx.","Joydeep Goswami leaves Illumina, stays as advisor through June 30; departure not due to disagreement.","Jakob Wedel named Chief Strategy and Corporate Development Officer, effective immediately.","Dhingra receives $650k base salary, $500k cash sign-on, $3.5M equity grant (70% PSUs, 30% RSUs), $15k monthly travel stipend.","Illumina reaffirms Q1 2024 and full-year 2024 financial guidance as announced on February 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239648,"accession_number":"0001110803-24-000007","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-02-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina Q4 rev $1.12B (+4% YoY), GAAP EPS $(1.11), non-GAAP $0.14; FY guide flat","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $1.12B, up 4% YoY (4% constant currency); GAAP gross margin 60.1%.","GAAP diluted loss per share $(1.11) vs $(0.89) in Q4 2022; non-GAAP EPS $0.14 unchanged.","FY 2023 revenue $4.5B down 2% YoY; GAAP loss per share $(7.34) (incl $821M GRAIL impairment).","Shipped 79 NovaSeq X in Q4, 352 in FY 2023; FY 2024 Core Illumina revenue flat, non-GAAP op margin ~20%.","GRAIL divestiture via sale or capital markets targeted to finalize terms by Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":4504000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239647,"accession_number":"0001110803-24-000002","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina Q4 rev $1.115B (+3%), FY rev $4.497B (-2%); shipped 352 NovaSeq X in FY23","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $1,115M Q4 (+3% YoY); full-year $4,497M (-2% YoY).","Core Illumina revenue $1,090M Q4 (+2%); full-year $4,431M (-3%).","Shipped 79 NovaSeq X instruments in Q4 and 352 in fiscal 2023.","Consolidated GAAP operating margin (15.5%) Q4, (24.0%) FY; non-GAAP margins 3.8% and 5.3%.","Preliminary results subject to adjustment; full Q4/FY results due Feb 8, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-7.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":4504000000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239645,"accession_number":"0001110803-24-000004","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K/A","filed_at":"2024-01-09T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Illumina estimates $43M impairment charge for Foster City campus exit in Q4 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Right-of-use asset and leasehold improvement impairment charges estimated at $43M for Q4 2023.","Charges relate to exiting a portion of the Foster City, California campus.","Company previously reported $182M in assets tied to the campus as of Oct 1, 2023.","Illumina continues evaluating options for the remainder of the Foster City campus; further charges possible but not yet estimable.","Charges will be excluded from non-GAAP metrics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239646,"accession_number":"0000950157-24-000024","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Illumina CCO Susan Tousi departs; Bas Verhoef named interim CCO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Susan Tousi, Chief Commercial Officer, leaves Illumina effective January 5, 2024.","Bas Verhoef, Head of Region – Europe, appointed Interim Chief Commercial Officer.","Announcement made on January 4, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257160,"accession_number":"0001110803-23-000088","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K/A","filed_at":"2023-11-13T23:59:59+00:00","items":["2.05"],"status":"ready","headline":"Illumina incurs $54M impairment charge for i3 campus exit; Foster City charges pending","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Incurred ~$54M in right-of-use asset and leasehold impairment charges in 2023 for exiting i3 campus in San Diego.","As of Oct 1, 2023, Foster City campus assets total ~$182M; expects charges from partial exit but cannot yet estimate.","Charges related to real estate footprint reduction will be excluded from non-GAAP financial metrics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257161,"accession_number":"0001110803-23-000085","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina Q3 GAAP loss $4.77/sh on $821M GRAIL impairment; cuts FY2023 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.12B flat YoY; GAAP diluted loss per share $(4.77) includes $821M GRAIL goodwill impairment.","Non-GAAP diluted EPS $0.33 vs $0.34 YoY; core Illumina revenue guided down 3-4% for FY2023.","Shipped 97 NovaSeq X instruments in Q3; FY2023 placement target raised to 330-340 units.","New CEO Jacob Thaysen started Sept 25; board special committee formed for GRAIL divestiture process.","FY2023 non-GAAP diluted EPS guidance lowered to $0.60-$0.70 from prior $0.75-$0.90 (implied)."],"consensus_eps_estimate":null,"consensus_eps_actual":-6.23,"consensus_revenue_estimate":null,"consensus_revenue_actual":3382000000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257159,"accession_number":"0001110803-23-000078","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K/A","filed_at":"2023-11-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Illumina amends CEO Jacob Thaysen's offer letter to extend stock purchase window and clarify ownership guidelines","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amended offer letter dated Nov 8, 2023 extends matching RSU purchase window from 90 days to 12 months after start date of Sept 25, 2023.","Matching RSU grant value up to $1,000,000 based on shares purchased under qualified trading plan; vesting on third anniversary subject to continued employment and holding.","Offer letter now explicitly subjects Thaysen to Illumina's Stock Ownership Guidelines requiring ownership of 6 times base salary within five years.","Thaysen's original appointment as CEO effective Sept 25, 2023 was reported in Sept 5, 2023 8-K; this amendment refines equity and ownership terms."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":257158,"accession_number":"0001110803-23-000069","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K/A","filed_at":"2023-10-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Illumina decides to hold annual advisory votes on executive compensation until 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Following May 25, 2023 shareholder vote, company will continue annual say-on-pay votes.","Next required advisory vote on frequency of such votes is no later than 2029 Annual Meeting.","Decision reflected in this Form 8-K/A filed October 18, 2023.","No other changes from original 8-K reporting voting results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274493,"accession_number":"0001110803-23-000067","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2023-09-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Illumina CMO Phil Febbo departs; separation agreement provides $600K salary continuation","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Medical Officer Phil Febbo departed on August 7, 2023.","Separation Agreement signed September 5, 2023: one year base salary ($600,000).","COBRA health insurance premiums paid for 12 months; executive physical benefits for 2023.","Future filing of Separation Agreement as exhibit to upcoming Form 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274492,"accession_number":"0000950157-23-000929","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2023-09-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Illumina appoints Jacob Thaysen as permanent CEO effective Sept 25, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jacob Thaysen, formerly SVP at Agilent, named CEO and Board member starting Sept 25.","Thaysen will receive $1M base salary, 125% target bonus, and $10M annual equity grants.","One-time equity make-whole grant of $3.5M and $500K cash bonus for forfeited Agilent awards.","Interim CEO Charles Dadswell resumes his role as SVP and General Counsel.","Thaysen drove Agilent's Life Sciences division to ~$4B revenue and ~30% operating margin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274491,"accession_number":"0001110803-23-000061","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Illumina CMO Phil Febbo departs Aug 7; CTO Alex Aravanis departs Aug 9, replaced by Steven Barnard","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Phil Febbo, Chief Medical Officer, departed Illumina on August 7, 2023.","Dr. Alex Aravanis, Chief Technology Officer, departing August 9 to pursue another opportunity.","Dr. Steven Barnard appointed CTO effective immediately; Barnard joined Illumina in 1998 as first scientist.","Barnard previously VP of Global Advanced Science, holds >100 patents, led NovaSeq X series development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274490,"accession_number":"0001110803-23-000060","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Illumina Q2 revenue up 1% to $1.18B, non-GAAP EPS $0.32, ships 109 NovaSeq X; guides FY23 non-GAAP EPS $0.75-0.90","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.176B (+1% YoY, +8% QoQ); GAAP loss per share $(1.48) vs $(3.40) (incl. $609M legal contingency).","Non-GAAP diluted EPS $0.32 vs $0.57; non-GAAP gross margin 66.5% vs 69.4%.","Shipped 109 NovaSeq X instruments in Q2; FY2023 supply capacity now >390 instruments.","FY2023 guidance: rev growth ~1%, GAAP loss $(2.08)-(1.93), non-GAAP EPS $0.75-$0.90.","Headwinds: cautious customer spending, slow China recovery, temporary decline in high-throughput consumables."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":2263000000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":274489,"accession_number":"0001110803-23-000054","cik":1110803,"company_name":"ILLUMINA, INC.","ticker":"ILMN","form_type":"8-K/A","filed_at":"2023-07-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Illumina interim CEO Dadswell gets $50k/month stipend, bonus raised to 100%","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board approved $50,000 per month stipend for Charles Dadswell retroactive to June 1, 2023, through month permanent CEO appointed.","Dadswell's target bonus increased from 60% to 100% of $600k base salary for his tenure as interim CEO.","Additional compensation reflects increased responsibilities; Dadswell continues as General Counsel.","Bonus achievement tied to company revenue and operating income objectives, subject to Board negative discretion.","No family relationships or related party transactions with other officers or directors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":22720722413.547184,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-07-18T23:59:59+00:00|274489"}